DE602007005353D1 - PyrazoloÄ1,5-aÜpyrimidine Derivate zur Verwendung in der Behandlung von Morbus Alzheimer und verwandten Leiden - Google Patents
PyrazoloÄ1,5-aÜpyrimidine Derivate zur Verwendung in der Behandlung von Morbus Alzheimer und verwandten LeidenInfo
- Publication number
- DE602007005353D1 DE602007005353D1 DE602007005353T DE602007005353T DE602007005353D1 DE 602007005353 D1 DE602007005353 D1 DE 602007005353D1 DE 602007005353 T DE602007005353 T DE 602007005353T DE 602007005353 T DE602007005353 T DE 602007005353T DE 602007005353 D1 DE602007005353 D1 DE 602007005353D1
- Authority
- DE
- Germany
- Prior art keywords
- pyrazolo
- alzheimer
- disease
- treatment
- related conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0601638.0A GB0601638D0 (en) | 2006-01-27 | 2006-01-27 | Therapeutic treatment |
| PCT/GB2007/050036 WO2007085873A1 (en) | 2006-01-27 | 2007-01-23 | Treatment of alzheimer's disease and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007005353D1 true DE602007005353D1 (de) | 2010-04-29 |
Family
ID=36060954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602007005353T Active DE602007005353D1 (de) | 2006-01-27 | 2007-01-23 | PyrazoloÄ1,5-aÜpyrimidine Derivate zur Verwendung in der Behandlung von Morbus Alzheimer und verwandten Leiden |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100240647A1 (de) |
| EP (1) | EP1981509B1 (de) |
| JP (1) | JP2009524635A (de) |
| AT (1) | ATE460936T1 (de) |
| AU (1) | AU2007209166A1 (de) |
| CA (1) | CA2640386A1 (de) |
| DE (1) | DE602007005353D1 (de) |
| GB (1) | GB0601638D0 (de) |
| WO (1) | WO2007085873A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006088246A1 (ja) * | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| JP2010534206A (ja) * | 2007-07-20 | 2010-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| EP2265603B1 (de) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitoren des bmp-signalpfades |
| EP2320737B1 (de) | 2008-08-05 | 2013-07-17 | Merck Sharp & Dohme Corp. | Pyrazolo-[1,5-a]-pyridine als mark-hemmer |
| EP2387315B1 (de) * | 2009-01-16 | 2015-07-15 | Merck Sharp & Dohme Corp. | Imidazo-[1,2-a-]pyridine und imidazo-[1,2-b-]pyridazine als mark-hemmer |
| WO2011087999A1 (en) | 2010-01-14 | 2011-07-21 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidines as mark inhibitors |
| WO2012045451A1 (en) * | 2010-10-05 | 2012-04-12 | Ludwig-Maximilians-Universitaet Muenchen | Novel therapeutic treatment of progranulin-dependent diseases |
| EP2970311A4 (de) | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | Bmp-hemmer und verfahren zur verwendung davon |
| US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1514558A1 (de) * | 2003-09-15 | 2005-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Verwendung von MARKK oder MARKK-Antagonisten zur Behandlung von Pathologien die von einer erhöhten oder reduzierten Phosphorylierung des MARK- oder Tau-Proteins charakterisiert ist |
| ZA200704476B (en) * | 2004-11-04 | 2008-09-25 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
-
2006
- 2006-01-27 GB GBGB0601638.0A patent/GB0601638D0/en not_active Ceased
-
2007
- 2007-01-23 AT AT07705350T patent/ATE460936T1/de not_active IP Right Cessation
- 2007-01-23 CA CA002640386A patent/CA2640386A1/en not_active Abandoned
- 2007-01-23 WO PCT/GB2007/050036 patent/WO2007085873A1/en active Application Filing
- 2007-01-23 JP JP2008551887A patent/JP2009524635A/ja not_active Withdrawn
- 2007-01-23 EP EP07705350A patent/EP1981509B1/de not_active Not-in-force
- 2007-01-23 AU AU2007209166A patent/AU2007209166A1/en not_active Abandoned
- 2007-01-23 US US12/223,157 patent/US20100240647A1/en not_active Abandoned
- 2007-01-23 DE DE602007005353T patent/DE602007005353D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2640386A1 (en) | 2007-08-02 |
| EP1981509A1 (de) | 2008-10-22 |
| ATE460936T1 (de) | 2010-04-15 |
| WO2007085873A1 (en) | 2007-08-02 |
| AU2007209166A1 (en) | 2007-08-02 |
| EP1981509B1 (de) | 2010-03-17 |
| US20100240647A1 (en) | 2010-09-23 |
| JP2009524635A (ja) | 2009-07-02 |
| GB0601638D0 (en) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE460936T1 (de) | Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden | |
| DE602007012363D1 (de) | 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
| ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
| TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| DE602005022113D1 (de) | Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| NO20064456L (no) | Thiadiazolidinoner som GSK-3 inhibitorer | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| JO2629B1 (en) | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| DE602004020685D1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| EA201100872A1 (ru) | Производные хиназолинамида | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |